Warrants of series TO3 were subscribed to approximately 77 percent and PEPTONIC medical AB receives approximately SEK 7.6 million
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW.
PEPTONIC medical AB ("Peptonic" or "the Company") today announces the outcome of the exercise of warrants of series TO3, which were issued in connection with the Company’s rights issue of units on Spotlight Stock Market in January 2023. In total, 151,154,495 warrants of series TO3 were exercised, corresponding to approximately 77.0 percent of the total number of outstanding warrants of series TO3, for subscription of 151,154,495 shares at a subscription price of SEK 0.05 per share. Peptonic will receive approximately SEK 7.6 million before issuing costs through the exercise of the warrants of series TO3.
Background:
The exercise period for exercise of the warrants of series TO3 took place during the period from and including November 2, 2023, up to and including November 16, 2023. The subscription price per share for exercising the warrants of series TO3 was set to SEK 0.05.
In total, 151,154,495 warrants of series TO3 were exercised for subscription of 151,154,495 shares, meaning that approximately 77.0 percent of all outstanding warrants of series TO3 were exercised for subscription of shares.
Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.
Number of shares, share capital and dilution
Through the exercise of the warrants of series TO3, the number of shares in Peptonic increases by 151,154,495 shares, from 1,383,691,101 shares (following registration of the share issue that was resolved by the board of directors on November 15, 2023) to a total of 1,534,845,596 shares. The share capital will increase by 3,778,862.38 SEK, from approximately SEK 34,592,277.53 (following registration of the share issue that was resolved by the board of directors on November 15, 2023) to SEK 38,371,139.91.
For existing shareholders who did not exercise any warrants of series TO3, the dilution amounts to approximately 9.8 percent of the number of shares and votes in the Company.
Advisers
Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal adviser to Peptonic in connection with the utilization of the warrants of series TO3.
For further information, please contact:
Erik Sundquist, CEO
Phone: + 46 722 49 90 43
Email: erik.sundquist@peptonicmedical.se
About PEPTONIC medical AB
Peptonic Medical AB is an innovative Swedish biomedical company engaged in research, development, and sales of unique medical treatments in the field of women's intimate health. Under the brand VagiVital®, the product portfolio encompasses treatments for various conditions such as vaginal atrophy, bacterial vaginosis, and urinary tract infections. These clinically tested products address the growing demand for intimate self-care within the business concept of Diagnose, Treat, Prevent. Sweden serves as the reference market to facilitate geographic expansion in collaboration with local distributors. The United States is the largest market in terms of sales. The company is headquartered in Stockholm, Sweden, with a sales office in New York, NY, and an R&D unit in Caesarea, Israel. Peptonic Medical also has a wholly owned subsidiary, Lune Oy, in Finland, focusing on sustainable period products sold under the Lunette®️ brand (www.lunette.com). The company's shares have been listed on www.spotlightstockmarket.com since 2014.
Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
This information is information that PEPTONIC medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 22.30 (CET) on November 19, 2023.